MLYS

13.50

0.37% 0.05

Handel nachbörslich: 13.50

Mineralys Therapeutics Inc (MLYS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$13.45

Offen:

$13.48

24-Stunden-Volumen:

93,852

Relative Volume:

0.63

Marktkapitalisierung:

$671.31M

Einnahmen:

Nettoeinkommen (Verlust:

$-119.67M

KGV:

-9.5711

EPS:

-1.4105

Netto-Cashflow:

$-97.30M

1W Leistung:

-2.81%

1M Leistung:

-2.74%

6M Leistung:

+4.25%

1J Leistung:

+62.45%

1-Tages-Spanne:

$13.41

$13.75

1-Wochen-Bereich:

$12.57

$14.05

52-Wochen-Spanne:

$5.85

$16.91

Mineralys Therapeutics Inc Stock (MLYS) Company Profile

Firmenname

Mineralys Therapeutics Inc

Sektor

Healthcare (1180)

Branche

Biotechnology (680)

Telefon

(888) 378-6240

Adresse

150 N. RADNOR CHESTER ROAD, RADNOR

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-12

Neueste SEC-Einreichungen

MLYS's Discussions on Twitter

Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-03-07	Eingeleitet	BofA Securities	Buy
2023-03-07	Eingeleitet	Credit Suisse	Outperform
2023-03-07	Eingeleitet	Evercore ISI	Outperform
2023-03-07	Eingeleitet	Guggenheim	Buy
2023-03-07	Eingeleitet	Stifel	Buy
2023-03-07	Eingeleitet	Wells Fargo	Overweight

Alle ansehen

Mineralys Therapeutics Inc Aktie (MLYS) Neueste Nachrichten

Nov 04, 2024

Mineralys Therapeutics to Announce Third Quarter 2024 - GlobeNewswire

Nov 04, 2024

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024 - Marketscreener.com

Nov 04, 2024

Nov 03, 2024

Objective long/short (MLYS) Report - Stock Traders Daily

Nov 03, 2024

Nov 02, 2024

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial - MSN

Nov 02, 2024

Oct 31, 2024

Mineralys Therapeutics (NASDAQ:MLYS) Receives "Buy" Rating from HC Wainwright - MarketBeat

Oct 31, 2024

Oct 30, 2024

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension - The Manila Times

Oct 30, 2024

Oct 29, 2024

Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock - MSN

Oct 29, 2024

Oct 24, 2024

Mineralys Therapeutics to Host Virtual Event on Hypertension Treatment Advances - MyChesCo

Oct 24, 2024

Oct 23, 2024

When the Price of (MLYS) Talks, People Listen - Stock Traders Daily

Oct 23, 2024

Oct 22, 2024

Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 - The Manila Times

Oct 22, 2024

Mineralys to Host Virtual KOL Event on the Unmet Medical - GlobeNewswire

Oct 22, 2024

Oct 20, 2024

We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate - Yahoo Finance

Oct 20, 2024

Oct 17, 2024

Hypertension Clinical Trials 2024: FDA Approvals, Medication, - openPR

Oct 17, 2024

Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail

Oct 17, 2024

Oct 16, 2024

Mineralys Therapeutics CEO sells $206,433 in stock - Investing.com

Oct 16, 2024

Mineralys Therapeutics CEO sells $206,433 in stock By Investing.com - Investing.com Canada

Oct 16, 2024

Mineralys therapeutics CFO Adam Levy sells $146,003 in stock By Investing.com - Investing.com South Africa

Oct 16, 2024

Mineralys therapeutics CFO Adam Levy sells $146,003 in stock - Investing.com

Oct 16, 2024

Oct 15, 2024